Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
Scienture Holdings (NASDAQ: SCNX) announced that Dr. Narasimhan Mani, President of Scienture, will participate as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) in India. The conference is scheduled for January 23-25, 2025, at BITS Pilani, Hyderabad Campus.
Dr. Mani will present on the specialty pharmaceutical industry, focusing on technology-driven product innovations and efficient market strategies for improving patient access to novel therapies. He will also participate in panel discussions about global pharmaceutical industry trends, portfolio development, breakthrough technology platforms, and commercialization strategies.
Scienture Holdings (NASDAQ: SCNX) ha annunciato che il Dr. Narasimhan Mani, Presidente di Scienture, parteciperà come relatore invitato e panelista all'8ª Conferenza Annuale della Società per lo Studio degli Xenobiotici (SSX) in India. La conferenza si terrà dal 23 al 25 gennaio 2025, presso il campus di BITS Pilani, Hyderabad.
Il Dr. Mani presenterà sull'industria farmaceutica specializzata, concentrandosi sulle innovazioni di prodotto guidate dalla tecnologia e su strategie di mercato efficienti per migliorare l'accesso dei pazienti a terapie innovative. Parteciperà anche a discussioni di panel sulle tendenze globali dell'industria farmaceutica, lo sviluppo del portafoglio, le piattaforme tecnologiche all'avanguardia e le strategie di commercializzazione.
Scienture Holdings (NASDAQ: SCNX) anunció que el Dr. Narasimhan Mani, Presidente de Scienture, participará como ponente invitado y panelista en la 8ª Conferencia Anual de la Sociedad para el Estudio de los Xenobióticos (SSX) en India. La conferencia está programada para el 23 al 25 de enero de 2025, en el Campus de BITS Pilani, Hyderabad.
El Dr. Mani presentará sobre la industria farmacéutica especializada, enfocándose en innovaciones de productos impulsadas por la tecnología y estrategias de mercado eficientes para mejorar el acceso de los pacientes a terapias novedosas. También participará en discusiones de panel sobre tendencias de la industria farmacéutica global, desarrollo de carteras, plataformas tecnológicas innovadoras y estrategias de comercialización.
Scienture Holdings (NASDAQ: SCNX)는 Dr. Narasimhan Mani, Scienture의 사장이 인도에서 개최되는 제8회 외래물질 연구 학회(SSX) 연례 회의에 초청 연사 및 패널리스트로 참여할 것이라고 발표했습니다. 이 회의는 2025년 1월 23일부터 25일까지 BITS Pilani, 하이데라바드 캠퍼스에서 열릴 예정입니다.
Mani 박사는 기술 중심의 제품 혁신과 환자의 새로운 치료 접근을 개선하기 위한 효율적인 시장 전략에 중점을 두고 특화된 제약 산업에 대해 발표할 예정입니다. 또한 그는 글로벌 제약 산업 동향, 포트폴리오 개발, 혁신적인 기술 플랫폼 및 상업화 전략에 대해 패널 토론에 참여할 것입니다.
Scienture Holdings (NASDAQ: SCNX) a annoncé que le Dr. Narasimhan Mani, Président de Scienture, participera en tant qu'intervenant invité et paneliste à la 8ème Conférence Annuelle de la Société pour l'Étude des Xenobiotiques (SSX) en Inde. La conférence est prévue du 23 au 25 janvier 2025, au campus de BITS Pilani, Hyderabad.
Le Dr. Mani présentera sur l'industrie pharmaceutique spécialisée, en mettant l'accent sur les innovations de produits axées sur la technologie et les stratégies de marché efficaces pour améliorer l'accès des patients à de nouvelles thérapies. Il participera également à des discussions de panel sur les tendances de l'industrie pharmaceutique mondiale, le développement de portefeuille, les plateformes technologiques révolutionnaires et les stratégies de commercialisation.
Scienture Holdings (NASDAQ: SCNX) gab bekannt, dass Dr. Narasimhan Mani, Präsident von Scienture, als eingeladener Referent und Panelist an der 8. Jahrestagung der Gesellschaft für die Studie von Xenobiotika (SSX) in Indien teilnehmen wird. Die Konferenz findet vom 23. bis 25. Januar 2025 auf dem Campus von BITS Pilani in Hyderabad statt.
Dr. Mani wird über die spezialisierte Pharmaindustrie sprechen, wobei der Schwerpunkt auf technologiegetriebenen Produktinnovationen und effizienten Marktstrategien zur Verbesserung des Patientenzugangs zu neuartigen Therapien liegt. Außerdem wird er an Podiumsdiskussionen über globale Trends in der Pharmaindustrie, Portfolioentwicklung, bahnbrechende Technologieplattformen und Kommerzialisierungsstrategien teilnehmen.
- None.
- None.
TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a Specialty Pharma company with a novel pipeline of brand products, is pleased to announce the participation of Narasimhan Mani, Ph.D., MBA (President of Scienture, LLC) as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, one of the premiere conferences organized in India specifically in the area of drug discovery and development. The conference will take place January 23-25, 2025, at BITS Pilani, Hyderabad Campus in Hyderabad, India.
Dr. Mani will deliver a presentation on the specialty pharmaceutical industry with a specific focus on technology driven product innovations and efficient go to market strategies for improving patient access to novel therapies. He will also engage in panel discussions to discuss current trends and developments in the global pharmaceutical industry with respect to portfolio development, breakthrough technology platforms and commercialization strategies.
About the SSX 2025 Conference
The Society for the Study of Xenobiotics, India is an affiliate society of the International Society for the Study of Xenobiotics (ISSX). It shares the same charter as ISSX and was created to share knowledge and training information related to ADMET sciences. SSX also functions to provide a forum for Indian DMPK/ADMET scientists to meet and exchange ideas. The SSX annual conference is one of the premiere events organized in India specifically in the area of drug discovery and development. SSX has successfully conducted 7 Annual International Conferences with a steady increase in the number of participants every year from the drug discovery and development research area and with participation by eminent scientists, students, academicians and industry experts.
The 2025 event will feature:
- Speakers, Including Highly Exeperienced Industry Veterans:
- Dr. Simon Haydar, Chief Scientific Officer, PI Health Sciences
- Dr. Kaushik Mitra – Scientific Director, DMPK, Janssen Research and Development, Johnson & Johnson
- Dr. Sagnik Chatterjee, Associate Principal Scientist, AstraZeneca
- Dr. Raju Subramanian, Executive Director, Gilead
- Dr. Narasimhan Mani, President, Scienture, LLC
- Expert Panels and Presentations
- Cultural Events and Networking
For more information, visit: https://ssxindia.in/.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products in development at Scienture, LLC, are across therapeutic areas, indications and cater to different market segments and channels. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contacts:
SCIENTURE HOLDINGS, INC.
SCIENTURE HOLDINGS, INC.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
When will Dr. Narasimhan Mani speak at the SSX Conference for Scienture Holdings (SCNX)?
What topics will Dr. Mani discuss at the 2025 SSX Conference representing SCNX?
Where is the 2025 SSX Conference being held for Scienture Holdings (SCNX)?
What is Dr. Mani's role at Scienture Holdings (SCNX)?
